Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cotargeting the AR (with MDV3100) and CLU (with OGX-011) synergistically enhanced apoptotic rates over that seen with MDV3100 or OGX-011 monotherapy and delayed CRPC LNCaP tumor and prostate-specific antigen (PSA) progression in vivo.
|
23786771 |
2013 |
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Age, PSA level, and BSI were found to be significant predictive factors for time to CRPC in patients with mHSPC.
|
28609769 |
2017 |
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Multivariate analysis identified prostate-specific antigen and alkaline phosphatase levels at CRPC onset, Gleason score ≥ 8, ECOG PS ≥2, less number of docetaxel cycles administered, and non-participation in CTs as independent predictors for a lower risk of CSS.
|
29695228 |
2018 |
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Recent studies have demonstrated that an angiotensin II receptor blocker (ARB) has the potential to decrease serum prostate-specific antigen (PSA) level and improve performance status in CRPC patients.
|
22430461 |
2012 |
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The majority of CRPC bone metastases (80%) was defined as AR-driven based on PCA analysis and high expression of the AR, AR co-regulators (FOXA1, HOXB13), and AR-regulated genes (KLK2, KLK3, NKX3.1, STEAP2, TMPRSS2); 20% were non-AR-driven.
|
27497761 |
2017 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to assess PSA surge phenomenon in castration-resistant prostate cancer (CRPC) patients treated with abiraterone and to correlate those variations with long-term treatment outcome.
|
28429372 |
2017 |
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PSA level should be used with caution as an end point in clinical trials using suramin therapy for hormone-refractory prostate cancer.
|
8637045 |
1996 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China.
|
28905815 |
2019 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conducted a double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic castration-resistant prostate cancer and a prostate-specific antigen doubling time of 10 months or less.
|
29420164 |
2018 |
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Higher levels of miR-21 were detected in patients with HRPC and ADPC with PSA level >4 ng/ml.
|
20842666 |
2011 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
PSA half-time (representing rate to PSA nadir after ADT), the incidence of, and time to CRPC occurrence, and cause-specific mortality rates were determined during the 3-10 years follow-up.
|
25731771 |
2015 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, 11βHSD2 activity, catalysing 11-ketotestosterone biosynthesis, was shown to be key in the production of prostate specific antigen and in the progression of prostate cancer to castration resistant prostate cancer.
|
30825506 |
2019 |
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We finally report a significant association between ERG rearrangements in therapy-naive tumors, CRPCs, and CTCs and magnitude of prostate-specific antigen decline (P=0.007) in CRPC patients treated with abiraterone acetate.
|
19339269 |
2009 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The combination has activity defined by PSA declines in CRPC but did not meet the protocol-specified end point for efficacy as defined by objective response rate.
|
29173976 |
2018 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
On multivariable analysis, higher PSA at castrate-resistant prostate cancer (4.67 vs. 4.4ng/mL, OR=0.57, P=0.02), shorter time from castrate-resistant prostate cancer to scan (7.9 vs. 14.6 months, OR=0.97, P=0.006) and higher PSA at scan (OR=2.91, P<0.0001) were significantly predictive of bone scan positivity.
|
31851457 |
2020 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.
|
19890632 |
2010 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phase I and II trial experience demonstrates the safety and tolerability of apalutamide, as well as its efficacy in effecting prostate-specific antigen response and radiographic-free survival in CRPC.
|
29695920 |
2018 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chemonaïve patients with CRPC on CAB and PSA-doubling time (DT) < 3 months were eligible.
|
19959380 |
2012 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present review, we ascertain the PSA dynamics and the mechanisms of the development of CRPC to assist in optimal utilization of the new treatments for mCRPC.
|
27270339 |
2017 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intratumoral and subcutaneous injections of HVJ-E are feasible and PSA response was observed in a subgroup of CRPC patients.
|
28497777 |
2017 |
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We retrospectively reviewed the following data from 113 patients with chemotherapy-naïve CRPC treated with enzalutamide: serum levels of prostate-specific antigen (PSA), testosterone, hemoglobin, total protein, albumin, and alkaline phosphatase (ALP); platelet, neutrophil, and lymphocyte counts; neutrophil-to-lymphocyte ratios (NLRs); and liver profiles.
|
30274641 |
2018 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cause specific survival and time to prostate specific antigen (castrate resistant prostate cancer) progression were analyzed.
|
28552710 |
2017 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cox proportional-hazards regression models were calculated to estimate effects of these variables on the time of progression to CRPC.On univariate and multivariate analyses, the presence of distant metastasis before ADT (hazard ratio [HR] 6.030, 95% confidence interval (CI) 3.229-11.263, P = .001), higher PSA nadir (HR 1.185, 95% CI 1.080-1.301, P = .001), a velocity of PSA decline >11 ng/mL per month (HR 2.124, 95% CI 1.195-3.750, P = .001), and a time to PSA nadir ≤9 months (HR 0.276, 95% CI 0.162-0.469, P = .004) were significantly associated with an increased risk of progression to CRPC.Patients with a rapidly decreasing PSA level in the initial phase of ADT are more likely to progress to CRPC.
|
28885333 |
2017 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multivariate Cox regression analysis demonstrated that Gleason grade group, prostate-specific antigen nadir (nPSA), and time to PSA nadir (TTN) were risk factors for progression to CRPC in mPCa patients.
|
31632505 |
2019 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the majority of castration-resistant prostate cancer (CRPC), prostate-specific antigen (PSA), product of a gene that is almost exclusively regulated by the androgen receptor (AR), still acts as a serum marker reflecting disease burden, indicating that AR signaling is activated even under castrate level of serum androgen.
|
23896594 |
2013 |